Abstract:In the past decade, thrombolytic therapy has become standard treatment of acute myocardial infarction. When the importance of thrombosis in the pathogenesis of acute infarction was fully recognised, several plasminogen activators were developed, streptokinase, urokinase, recombinant tissue-type plasminogen activator (t-PA, alteplase), anistreplase and saruplase (prourokinase). Thrombolytic agents are plasminogen activators which possess as a common characteristic the ability to activate plasminogen to plasmin, and result in fibrinolysis and varying degrees of depletion of circulating fibrinogen, factor V and factor VIII. A lot of animal experiments provided the basis for the rationale that recanalisation and reperfusion early in the course of myocardial infarction would limit myocardial necrosis, improve left ventricular function, and improve patient outcome. Native tissue plasminogen activator is normally secreted by vascular endothelium and the most important property of the drug is its relative fibrin specificity. Fibrin strikingly increases the rate of conversion of plasminogen to plasmin by t-PA. The isolation of the complementary DNA coding for t-PA, its insertion into the genome of Chinese hamster ovary cells, and its expression in suspension cultures of these cells have facilitated the large-scale production of t-PA, making it available as a drug for the treatment of acute myocardial infarction. A variety of dosage schemes have been used for alteplase, the standard schedule has been 100 mg given over 3 hours. Higher doses and faster administration (accelerated, front-loaded) are associated with higher patency rates. Alteplase has generally but not always been shown to have higher reocclusion rates than the non-fibrin-specific plasminogen activators. Reocclusion has been shown to be associated with adverse clinical outcome. Therefore, the rate of reocclusion is considered an important measure in evaluating thrombolytic regimens. The combination of alteplase with either urokinase or streptokinase has resulted in early patency rates comparable to alteplase alone, and low rates of reocclusion. Large, randomised clinical trials have demonstrated that thrombolytic therapy reduces mortality significantly in patients with ST elevation treated within the first 6 to 12 hours of acute myocardial infarction. As compared to an overall reduction of mortality with thrombolytic treatment, neither the GISSI-2/international trial nor the Third International Study of Infarct Survival (ISIS-3) trial of more than 60,000 patients found a difference in associated mortality between the use of streptokinase and the use of t-PA, or between the use of these agents and that of anistreplase. The addition of subcutaneous heparin to the regimens did not significantly reduce mortality as compared with no use of heparin.(ABSTRACT TRUNCATED AT 400 WORDS)

Myocardial Infarction Following Recombinant Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke: a Dangerous Complication.

Cerebral Ischemic Reperfusion Injuries (CIRI)

Study of intravenous thrombolysis with recombinant tissue plasminogen activator(rtPA)in isolatedpenetrating artery territory infarcts

Studing of the Special Problems in Thrombolysis Cure of Acute Myocardial Infarction

Intracerebral Hemorrhage after Intravenous Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction

Effect and safety of rt-PA combined with Hydroxyethyl starch in the treatment of acute cerebral infarction

Tissue Plasminogen Activator in Acute Cardiac Arrest

Multi-mode MRI-based Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator(rtpa)reduces Hemorrhagic Transformation in Ischemic Stroke Patients

The efficiency and safety of the intravenous thrombolysis using recombinant plasminogen activator (rt-PA) for acute cerebral ischemia

Intra-Arterial Local Thrombolysis for Hyperacute Cerebral Infarction with Recombinant Tissue Plasminogen Activato

Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis

[t-PA in thrombolytic therapy of acute myocardial infarct]

Therapeutic Effect of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction at Different Times.

Intravenous Thrombolytic Therapy among 25 Patients with Acute Ischemic Stroke

Rupture of Anterior Communicating Artery Aneurysm after Intravenous Thrombolysis for Acute Ischemic Stroke: A Case Report

Intra-arterial Thrombolysis with R-Tpa for the Treatment of Acute Cerebral Infarction 6 to 9 Hours after Onset

Efficacy of Thrombolysis by Intravenous Recombinant Tissue Plasminogen Activator in Hyperacute Cerebral Infarction

Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke

Circulating Inflammatory Biomarkers Level Before Thrombolysis for Acute Ischemic Stroke Predicts Symptomatic Intracerebral Hemorrhage.

The Clinical Study of Thrombolysis with rt-PA in Acute Ischemic Stroke

Efficacy of Recombinant Tissue—type Plasminogen Activator Thrombolysis and Primary Coronary Stenting after Acute Myocardial Infarction